2,4-二氯溴苄 | 20443-99-6

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 芳香烃
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,4-二氯溴苄
• 中文别名: 2,4-二氯苄基溴；2,4-二氯苄溴
• 英文名称: 2,4-dichlorobenzyl bromide
• 英文别名: 1-(bromomethyl)-2,4-dichlorobenzene
• CAS: 20443-99-6
• 化学式: C₇H₅BrCl₂
• mdl: MFCD03208523
• 分子量: 239.927
• InChiKey: RGLQSFFFIREZFV-UHFFFAOYSA-N

物化性质

• 熔点：
  32 °C
• 沸点：
  126-133 °C(Press: 8 Torr)
• 密度：
  1.679±0.06 g/cm3(Predicted)
• 溶解度：
  溶于甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

安全信息

• 海关编码：
  2903999090
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2,4-Dichlorobenzyl bromide
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2,4-Dichlorobenzyl bromide
CAS number: 20443-99-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5BrCl2
Molecular weight: 239.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,4-二氯溴苄 在 potassium dihydrogenphosphate 、 sodium methylate 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 38.17h， 生成 Methyl 3-cyano-4-[(2,4-dichlorophenyl)methylsulfanyl]-3-hydroxybutanoate
  参考文献：
  名称：

  ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. Design and Synthesis of 2-Substituted Butanedioic Acids as Novel, Potent Inhibitors of the Enzyme

  摘要：

  ATP-citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Inhibitors of the enzyme represent a potentially novel class of hypolipidemic agent, which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties. A series of a-substituted butanedioic acids have been designed and synthesized as inhibitors of the enzyme, The best compounds, 58, 68, 71, 74 have reversible K-i's in the 1-3 mu M range against the isolated rat enzyme, As representative of this compound class, 58, has been shown to exert its inhibitory action through a mainly competitive mechanism with respect to citrate and a noncompetitive one with respect to CoA. None of the inhibitors were able to inhibit cholesterol and/or fatty acid synthesis in HepG2 cells. This has been attributed to the adverse physicochemical properties of the molecules leading to a lack of cell penetration. Despite this, a lead structural class of compound has been identified with the potential for modification into potent, cell-penetrant, and efficacious inhibitors of ATP-citrate lyase.

  DOI：

  10.1021/jm960167w
• 作为产物：
  描述：

  2,4-二氯苄醇 在 三溴化磷 作用下， 以 乙醚 为溶剂， 反应 0.5h， 生成 2,4-二氯溴苄
  参考文献：
  名称：

  新型间乙酰氨基酚嵌入 [1,2,3]-三唑衍生物的合成、对接和生物活性

  摘要：

  ERα控制乳腺癌的乳腺组织发育和进展。在我们寻找靶向雌激素受体 α 配体结合域的新型化合物时，我们确定了“N-(3-((1H-1,2,3-triazol-4-yl)methoxy)phenyl)乙酰胺”衍生物作为先导化合物. 对接研究表明，当对接至 1XP6 时，间乙酰氨基酚衍生物的对接得分良好。已经合成、表征和评估了一系列间乙酰氨基酚衍生物的细胞毒性、抗细菌和抗氧化活性。在测试的 12 种杂化化合物中，“ 7a、7g、7h和7i”衍生物显示出良好的细胞毒性，对 MCF-7 细胞系的IC 50值为 <22 µg/mL。化合物“ 7a、7d、7e、7f、7h、7i、7j、7k和7l”显示出出色的抗氧化活性，IC 50值 < 30 µM，而化合物“ 7a、7b、7c、7d、7g、7j、7k和7l”显示中等抗菌活性，MIC 值 <300 µM。

  DOI：

  10.1016/j.molstruc.2021.130786

文献信息

• Synthesis and evaluation of antioxidant activities of novel 1,3,4-oxadiazole and imine containing 1$H$-benzimidazoles
  作者：Ayşe Selen ALP、Gülgün KILCIGİL、Elçin Deniz ÖZDAMAR、Tülay ÇOBAN、Binay EKE

  DOI：10.3906/kim-1403-44

  日期：——

  Some novel 2-(substitutedbenzylthio)-5-((2-(4-substitutedphenyl)-1H-benzo[d]imidazol-1-yl)methyl)-1,3,4-oxadiazoles (5--12) and 2-(2-(4-chlorophenyl)-1H-benzo[d]imidazol-1-yl)-N'-(arylmethylene)acetohydrazide derivatives (13--22) were prepared and their in vitro antioxidant properties were investigated by determination of rat liver microsomal NADPH-dependent inhibition of lipid peroxidation (LP) levels and microsomal ethoxyresorufin O-deethylase (EROD) activity. Compound 18 was found to be the most active compound with 100% inhibition on LP level and 92% inhibition on EROD. Compounds 4b, 17, and 19 showed the strongest inhibitory effect (97%) on EROD. The free radical scavenging capacities of the compounds were also tested in vitro determining the interaction of the stable free radical 2,2,diphenyl-1-picrylhydrazyl (DPPH), and compounds 4a and 4b exhibited good antioxidant activities.

  一些新型2-（取代苄硫基）-5-（（2-（4-取代苯基）-1H-苯并[d]咪唑-1-基）甲基）-1,3,4-噁二唑（5-12）和2-（2-（4-氯苯基）-1H-苯并[d]咪唑-1-基）-N'-(芳亚甲基)乙酰肼衍生物（13-22）被合成，并通过测定大鼠肝微粒体NADPH依赖性脂质过氧化（LP）水平和微粒体乙氧基罗丹明O-去乙基酶（EROD）活性，研究了它们在体外的抗氧化性质。化合物18被发现是最活跃的化合物，对LP水平的抑制达到100%，对EROD的抑制达到92%。化合物4b、17和19显示出对EROD最强的抑制效果（97%）。这些化合物的自由基清除能力也在体外通过测定与稳定自由基2,2-二苯基-1-苦基肼（DPPH）的相互作用进行了测试，化合物4a和4b表现出良好的抗氧化活性。
• Sulfonamide peri-substituted bicyclics for occlusive artery disease
  申请人：Singh Jasbir

  公开号：US20060079520A1

  公开（公告）日：2006-04-13

  Acyl sulfonamide, peri-substituted, fused bicyclic ring compounds useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the general formula A representative example is:

  酰基磺酰胺，带有周取代的融合双环环化合物，用于治疗或预防前列腺素介导的疾病或症状。这些化合物的一般公式为 代表性示例是：
• FLAP MODULATORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20140221310A1

  公开（公告）日：2014-08-07

  The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R 1 , L and R 2 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

  本发明涉及式（I）化合物，或其形式，其中环A，R1，L和R2如本文所定义，作为FLAP调节剂有用。该发明还涉及包含式（I）化合物的药物组合物。制备和使用式（I）化合物的方法也属于本发明的范围。
• Construction of Functionalized Carbocycles Having Contiguous Tertiary Carbinol and All-Carbon Stereogenic Centers
  作者：Chennakesava Reddy、Srinivasarao Arulananda Babu、Nayyar Ahmad Aslam、Vadla Rajkumar

  DOI：10.1002/ejoc.201201382

  日期：2013.4

  A highly stereoselective protocol is reported for customizing functionalized carbocyclic building blocks (β-hydroxy esters) and bicyclic lactones with a stereoarray that contains contiguous tertiary carbinol and all-carbon stereocenters. The efficient asymmetric induction and diastereofacial selective addition of allyl and propargyl indiums to hindered α,α-disubstituted cycloalkanones is presented

  报告了一种高度立体选择性的协议，用于定制功能化碳环结构单元（β-羟基酯）和双环内酯，其立体阵列包含连续的叔甲醇和全碳立体中心。介绍了烯丙基和炔丙基铟与受阻 α,α-二取代环烷酮的有效不对称诱导和非对映选择性加成。代表性产物的立体化学是从单晶 X 射线晶体结构分析中明确建立的，并提出了一种合理的反应途径来支持高非对映面选择性。
• Pyrimidine-thioalkyl and alkylether compounds
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：EP1247804A1

  公开（公告）日：2002-10-09

  The subject invention relates to pyrimidine-thioalkyl and alkylether compounds of Formula I and pyrimidine-thioalkyl and alkylethers of Formula IA, namely the compounds of Formula I where R4 is selected from the group consisting of -H or -NR15R16 where R15 is -H and R16 is -H, C1-C6 alkyl, -NH2 or R15 and R16 taken together with the -N form 1-pyrrolidino, 1-morpholino or 1-piperidino; and R6 is selected from the group consisting of -H, or halo (preferably -Cl); with the overall provisio that R4 and R6 are not both -H; The compounds of Formula IA are useful in the treatment of individuals who are HIV positive.

  该发明涉及Formula I的嘧啶硫代烷基和烷基醚化合物，以及Formula IA的嘧啶硫代烷基和烷基醚化合物，即Formula I中R4选自-H或-NR15R16的基团，其中R15为-H，R16为-H，C1-C6烷基，-NH2或R15和R16一起与-N形成1-吡咯啉基、1-吗啉基或1-哌啶基；以及R6选自-H或卤素（优选-Cl）的基团，总体规定是R4和R6不能同时为-H；Formula IA的化合物在治疗HIV阳性个体中是有用的。